Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Strategies; Reimbursement

Set Alert for Pricing Strategies and Reimbursement

Pricing Strategies

Multiple Molecules See UK Prices Double In March

Etoricoxib, letrozole and trimethoprim experienced triple-digit rises in their average UK trade prices in March, according to the latest figures from WaveData.

Market Intelligence Pricing Strategies

Austria Accepts Merck Commitments After ‘Predatory Pricing’ Undermined Generics

Merck has agreed to discontinue a “predatory strategy” for the company’s Temodal (temozolomide) oncology brand in Austria that kept generics out of the market, including by supplying the brand below cost price, under commitments offered to the country’s competition watchdog.

Compliance Market Access

Valeo Chalks Up Another Milestone For Canadian Enoxaparin Biosimilars

Canada’s Valeo Pharma insists it has “worked tirelessly to ensure a robust supply of Redesca,” after completing another milestone for the company’s enoxaparin biosimilar product.

Biosimilars Market Access

BGMA’s Smith Reflects On 25 Years Of Progress

As Warwick Smith steps down after 25 years as leader of the British Generic Manufacturers Association, he talks about how far the country’s off-patent industry has come over the last quarter-century – including the acceptance of generics, the advent of biosimilars, and how freedom of pricing has helped to keep costs low while maintaining sustainable pricing – in the first part of an exclusive interview with Generics Bulletin.

Leadership United Kingdom

Belgian Body Warns Over Price Erosion

With well over 3,000 off-patent medicines set for a price cut from the start of April in Belgium, local industry association Medaxes has voiced its support for government-led healthcare cost efficiencies but has warned of the risks of driving players out of the market with unsustainably low prices.

Belgium Pricing Strategies

AAM Urges Biden-Harris Administration To Increase Biosimilar Reimbursement

The AAM has urged the US Congress to increase biosimilar reimbursement through higher Medicare Part B add-on payments for biosimilars, based on a recent IQVIA report that has identified a correlation between Medicare payments and biosimilar adoption. The AAM has also urged the CMS to establish a shared savings program. 

United States Biosimilars
See All
UsernamePublicRestriction

Register